The geoepidemiology of primary biliary cirrhosis: Contrasts and comparisons with the spectrum of autoimmune diseases

Clinical Immunology

Volumn 91, Issue 2, 1999, Pages 206-218

  Parikh Patel, Arti ^a   Gold, Ellen ^a   Mackay, Ian R ^b   Gershwin, M Eric ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MONASH UNIVERSITY   (Australia)

Author keywords

Anti mitochondrial antibodies; Epidemiology; Primary biliary cirrhosis

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MITOCHONDRION ANTIBODY;

ALLELE; ARTICLE; AUTOIMMUNE DISEASE; CASE FINDING; COMPARATIVE STUDY; ENVIRONMENTAL FACTOR; GEOGRAPHIC DISTRIBUTION; HUMAN; INTRAHEPATIC BILE DUCT; LIVER FUNCTION TEST; MULTIGENE FAMILY; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; SEX DIFFERENCE;

EID: 0032932588     PISSN: 15216616     EISSN: None     Source Type: Journal    
DOI: 10.1006/clim.1999.4690     Document Type: Article

References (136)

1. Beeson P. B. Age and sex associations of 40 autoimmune diseases. Am. J. Med. 96:1994;457-462.
2. Gershwin M. E., Migliaccio C. T., Water J. V. D., Coppel R. L. Molecular considerations of primary biliary cirrhosis. Molecular Considerations of Primary Biliary Cirrhosis. 1998;Kluwer Academic, Hingham. p. 40-52.
3. Gershwin M. E. Molecular analysis of cytoplasmic autoantigens in liver disease. Rose N. R., Mackay I. R. Molecular Analysis of Cytoplasmic Autoantigens in Liver Disease. 1992;213-233 Academic Press, San Diego.
4. Sherlock S., Scheur P. J. The presentation and diagnosis of 100 patients with primary biliary cirrhosis. New Engl. J. Med. 289:1973;674-678.
5. Mahl T. C., Shockor W., Boyer J. L. Primary biliary cirrhosis: Survival of a large cohort of symptomatic and asymptomatic patients followed for 24 years. J. Hepatol. 20:1994;707-713.
6. Kato Y., Suzuki K., Kumogai M., Nishimura K., Miayamon H., Kobayashi K. Familial primary biliary cirrhosis. J. Gastroenterol. 75:1981;188-191.
7. Bach N., Schaffner F. Familial primary biliary cirrhosis. J. Hepatol. 20:1994;698-701.
8. Floreani A., Naccarato R., Chiaramonte M. Prevalence of familial disease in primary biliary cirrhosis in Italy. J. Hepatol. 26:1997;737-740.
9. Culp K. S., Fleming C. R., Duffy J. Autoimmune associations in primary biliary cirrhosis. Mayo Clin. Proc. 57:1982;365-370.
10. Hamlyn A. N., Sherlock S. The epidemiology of primary biliary cirrhosis: A survey of mortality in England and Wales. Gut. 15:1974;473-479.
11. Van Dam G. M., Gips C. H. Primary biliary cirrhosis (PBC) in an European country - A description of death rates in the Netherlands. Hepato-gastroenterology. 43:1996;906-913.
12. Metcalf J. V., Bhopal R. S., Gray J., Howel D., James O. F. W. Incidence and prevalence of primary biliary cirrhosis in the city of Newcastle-Upon-Tyne, England. Int. J. Epidemiol. 26:1997;830-836.
13. Triger D. R. Primary biliary cirrhosis: An epidemiological study. Br. Med. J. 281:1980;772-775.
14. Hamlyn A. N., Macklon A. F., James O. Primary biliary cirrhosis: A geographical clustering and symptomatic onset seasonality. Gut. 24:1983;940-945.
15. Myszor M., James O. F. W. The epidemiology of primary biliary cirrhosis in Northeast England: An increasingly common disease. Q. J. Med. 75:1990;377-385.
16. Hislop W. Primary biliary cirrhosis: An epidemiological study. Br. J. Med. 281:1980;772.
17. Goudie B., MacFarlane G., Boyle P. Epidemiology of antimitochondrial antibody seropositivity and primary biliary cirrhosis in west of Scotland. Gut. 28:1987;A1346.
18. Eriksson S., Lindgren S. The prevalence and clinical spectrum of primary biliary cirrhosis in a defined population. Scand. J. Gastro. 19:1984;971-976.
19. Lofgren J., Jarnerot G., Danielsson D., Hemdal I. Incidence and prevalence of primary biliary cirrhosis in a defined population in Sweden. Scand. J. Gastro. 20:1985;647-650.
20. Danielsson A., Boqvist L., Uddenfelt P. Epidemiology of primary biliary cirrhosis in a defined rural population in the northern part of Sweden. Hepatology. 11:1990;458-464.
21. Remmel T., Remmel H., Uibo R., Salupere V. Primary biliary cirrhosis in Estonia with special reference to incidence, prevalence, clinical features and outcome. Scand. J. Gastro. 30:1995;367-371.
22. Triger D. R., Berg P. A., Rodes J. Epidemiology of primary biliary cirrhosis. Liver. 4:1984;195-200.
23. Watson R. G. P., Angus P. W., Dewar M., Goss B., Sewell R. B., Smallwood R. A. Low prevalence of primary biliary cirrhosis in Victoria, Australia. Gut. 36:1995;927-930.
24. Witt-Sullivan H., Heathcote J., Cauch K., Blendis L., Ghent C., Katz A., Milner R. The demography of primary biliary cirrhosis in Ontario, Canada. Hepatology. 12:1990;98-105.
25. Kapelman B., Schaffner F. The natural history of primary biliary cirrhosis. Semin. Liv. Dis. 1:1981;273-281.
26. James O. F., Myszor M. Epidemiology and genetics of primary biliary cirrhosis. Progr. Liv. Dis. 9:1990;523-536.
27. Feizi T., Naccarato R., Sherlock S., Doniach D. Mitochondrial and other tissue antibodies in relatives of patients with primary biliary cirrhosis. Clin. Exp. Immunol. 10:1972;609-622.
28. Galbraith R. M., Smith M., Mackenzie R. M., Tee D. E., Doniach D., Williams R. High prevlence of seroimmunologic abnormalities in relatives of patients with chronic active hepatitis or primary biliary cirrhosis. New Engl. J. Med. 290:1974;63-69.
29. Shibasaki T., Shimada T., Morita T., Sakai O. Immunogenetical penetrance in patients with primary biliary cirrhosis. Japan J. Med. 29:1990;533-536.
30. Brind A. M., Bray G. P., Portmann B. C., Williams R. Prevalence and pattern of familial disease in primary biliary cirrhosis. Gut. 36:1995;615-617.
31. Lucey M. R., Neuberger J. M., Williams R. Primary biliary cirrhosis in men. Gut. 27:1986;1373-1376.
32. Rubel L. R., Rabin L., Seaff L. B., Licht H., Cuccherini B. A. Does primary biliary cirrhosis in men differ from primary biliary cirrhosis in women. Hepatology. 4:1984;671-677.
33. Ahmed S. A., Penhale W. J., Talal N. Sex hormones, immune responses and autoimmune diseases. Am. J. Pathol. 121:1985;531-551.
34. Roubinian J. R., Papoian W. J., Talal N. Androgenic hormones modulate autoantibody response and improve survival in murine lupus. J. Clin. Invest. 59:1977;1066-1070.
35. Schot L. P. C., Verheul A. M., Schuurs A. H. Effect of nondrolone decanoate on Sjögren's syndrome like disorders in NZB/NZW mice. Clin. Exp. Immunol. 57:1984;571-574.
36. Grossman C. J. Regulation of the immune system by sex steroids. Endocr. Rev. 5:1984;435-454.
37. Penhale W. J., Ahmed S. A. The effect of gonadectomy on the sex related expression of autoimmune thyroiditis in the thymectomized and irradiated rats. Am. J. Reprod. Immunol. 1:1981;326-330.
38. Chapel T. A., Burns R. E. Oral contraceptives and exacerbation of lupus erythematosus. Am. J. Obstet. Gynecol. 110:1971;366-369.
39. Jungens P., Dougados M., Pelissier C., Nahoul K., Tron F., Bach J. F. Influence of oral contraceptive therapy on the activity of systemic lupus erythematosus. Arthritis Rheum. 25:1982;618-623.
40. McKenna C. H., Weiman K. C., Schulman L. E. Oral contraceptives, rheumatic diseases, and autoantibodies. Arthritis Rheum. 12:1969;313-314.
41. Schleicher E. M. LE cells after oral contraceptives. Lancet. 1:1968;821-822.
42. Spiera H., C.M. P. Rheumatic symptoms and oral contraceptives. Lancet. 1:1969;571-572.
43. Garovich M., Agudelo C., Pisko E. Oral contraceptives and systemic lupus erythematosus. Arthritis Rheum. 23:1980;1396-1398.
44. Golding P. L., Brown R., Mason A. M. S., Taylor E. "Sicca complex" in liver disease. Br. Med. J. 4:1970;340-342.
45. Taylor P. V., Campbell J. M., Scott J. S. Presence of autoantibodies in women with unexplained infertility. Am. J. Obstet. Gynecol. 161:1989;377-379.
46. Cowchock S., Smith J. B., Gocial S. Antibodies to phospholipids and nuclear antigens in patients with related abortions. Am. J. Obstet. Gynecol. 155:1986;1002-1110.
47. Gleicher N., El-Roiey A., Confino E., Friberg J. Autoantibodies in reproductive failure: Is endometriosis an autoimmune disease. Obstet. Gynecol. 70:1987;115-122.
48. Gleicher N., El-Roiey A., Confino E., Friberg J. Reproductive failure because of autoantibodies: Unexplained infertility and pregnancy wastage. Am. J. Obstet. Gynecol. 160:1989;1376-1385.
49. LaBarbara A. R., Miller M. M., Ober C., Rebar R. W. Autoimmune etiology in premature ovarian failure. Am. J. Reprod. Immunol. 16:1988;115-122.
50. Geva E., Amit A., Lerner-Geva L., Lessing J. B. Autoimmunity and reproduction. Fertil. Steril. 67:1997;599-611.
51. Shelton A. J., Harger J. H., Dorman J. S., Kuller L. H., LaPorte R. E., Gill T. J. Association between familial autoimmune diseases and recurrent spontaneous abortions. Am. J. Reprod. Immunol. 32:1994;82-87.
52. Whelton M. J., Sherlock S. Pregnancy in patients with hepatic cirrhosis management outcomes. Lancet. 2:1968;995.
53. Ahrens E. H., Payne M. A., Kunkel H. G. Primary biliary cirrhosis. Medicine. 29:1950;299.
54. Bach J. F. Predictive medicine in autoimmune disease; from the identification of genetic predisposition and environmental influence to precocious immunotherapy. Clin. Immunol. Immunopathol. 72:1994;156-161.
55. Galbraith R. M., Eddleston A. L. W. F., Smith M. G. M., Williams R., McSween R. N., Watkinson G., Dick H., Kennedy L. A., Batchelor J. R. Histocompatibility antigens in autoimmune chronic hepatitis and primary biliary cirrhosis. Br. Med. J. 3:1974;604-605.
56. Bassendine M. F., Dewar P. J., James O. F. W. HLA-DR antigens in primary biliary cirrhosis: Lack of association. Gut. 26:1985;625-628.
57. Ercilla G., Pares A. Primary biliary cirrhosis associated with HLA-DRw3. Tissue Antigens. 14:1979;449-452.
58. Miyamori H., Kato Y., Kobayashi K., Hattori N. HLA antigens in Japanese patients with primary biliary cirrhosis and autoimmune hepatitis. Digestion. 26:1983;213-217.
59. Underhill J., Donaldson P., Bray G., Doherty D., Portmann B., Williams R. Susceptibility to primary biliary cirrhosis is associated with HLA-DR8-DQB1*402 haplotype. Hepatology. 16:1992;1404-1408.
60. Gregory W. L., Mehal W., Dunn A. N., Cavanagh G., Chapman R., Fleming K. A., Daly A. K., Idle J. R., James O. F., Bassendine M. F. Primary biliary cirrhosis: Contribution of HLA class II allele DR8. Queensland J. Med. 86:1993;393-399.
61. Onishi S., Sakamaki T., Maeda T. DNA typing of HLA class II genes DRB1*0803 increases the susceptibility of Japanese to primary biliary cirrhosis. J. Hepatol. 21:1994;1053-1060.
62. Robson S. C., Hift R. J., Kirsch R. E. Primary biliary cirrhosis: A retrospective survey at Groote Schuur Hospital, Cape Town. S. African Med. J. 78:1990;19-22.
63. Greenwood B. M. Autoimmune disease and parasitic infection in Nigerians. Lancet. 2:1968;380-382.
64. Clark I. A., Al-Yaman F. M., Cowden W. B., Rockett K. A. Does malarial tolerance through nitric oxide explain the low incidence of autoimmune disease in tropical Africa. Lancet. 348:1996;1492-1494.
65. Clark I. A., Rockett K. A., Cowden W. B. Possible central role of nitric oxide in conditions clinically similar to cerebral malaria. Lancet. 340:1992;894-896.
66. Rose N. R. The role of infection in the pathogenesis of autoimmune disease. Semin. Immunol. 10:1998;5-13.
67. Nygard N. R., Schwartz B. D. Infection and autoimmunity. Adv. Intern. Med. 38:1993;337-359.
68. Shoenfeld Y. Common infections, idiotypic dysregulation, autoantibody spread and induction of autoimmune diseases. J. Autoimmun. 9:1996;235-239.
69. Ginsberg-Fellner F., Witt M. E., Yagihashi S., Dobersen M. J., Taub F., Fedun B., McEvoy R. C., Roman S. H., Davies R. G., Cooper L. Z. Congenital rubella syndrome as a model for type 1 (insulin-dependent) diabetes mellitus: Increased prevalence of islet cell surface antibodies. Diabetologia. 27 Suppl:1984;87-89.
70. Yoon J. W., Ihm S. H., Kim K. W. Viruses as a triggering factor of type 1 diabetes and genetic markers related to the susceptibility to the virus-associated diabetes. Diabetes Res. Clin. Prac. 7:1989;S47-S58.
71. Wenzel B. E., Heesemann J., Wenzel K. W., Scriba P. C. Antibodies to plasmid-encoded proteins of enteropathogenic Yersinia in patients with autoimmune thyroid disease [letter]. Lancet. 1:1988;56.
72. Fernandes G. Dietary lipids and risk of autoimmune disease. Clin. Immunol. Immunopathol. 72:1994;193-197.
73. Johnston P. V. Dietary fats, eicosanoids and autoimmunity. Adv. Lipid Res. 21:1985;101-141.
74. Lagamere S., Yu B. P., Fernandes G. Studies on membrane lipid peroxidation in omega-3 fatty-acid-fed autoimmune mice: Effect of vitamin E supplementation. Adv. Exp. Med. Biol. 262:1990;95-103.
75. Fernandes G., Chandrasekar B., Venkatraman J. T., Tomar V., Zhao W. Increased transforming growth factors and decreased oncogene expression by omega-3 fatty-acids in the spleen delays the onset of autoimmune disease in B/W mice. J. Immunol. 152:1994;5979.
76. George J., Levy Y., Shoenfeld Y. Smoking and immunity: An additional player in the mosaic of autoimmunity. Scand. J. Immunol. 45:1997;1-6.
77. Becker C. G., Dubin T., Wiedemann H. P. Hypersensitivity to tobacco antigen. Proc. Natl. Acad. Sci. USA. 73:1976;1712-1716.
78. Francus T., Klein R. F., Staiano-coico L., Becker C. G., Siskind G. W. Effects of tobacco smoke on the immune system. J. Immunol. 140:1988;1823-1829.
79. Schwartz R. S. Autoimmunity and autoimmune diseases. Paul W. E. Autoimmunity and Autoimmune Diseases. 1993;1033-1097 Raven Press, Boca Raton.
80. Choy J. W., Becker C. G., Siskind G. W. Effects of tobacco glycoprotein (TGP) on the immune system- TGP is a T independent B cell mitogen for murine lymphoid cells. J. Immunol. 134:1985;3193-3198.
81. Butkowski R. J., Shen G. Q., Wieslander J., Michael A. F., Fish A. J. Characterization of type IV collagen NCI monomers and Goodpasture's antigen in human renal basement membranes. J. Biol. Chem. 115:1990;365-373.
82. Donaghy M., Rees A. J. Cigarette smoking and lung hemorrhage in glomerulonephritis caused by autoantibodies to glomerular basement membrane. Lancet. 2:1983;1390-1393.
83. Heufelder A. E., Wenzel B. E., Gorman C. A. Detection, cellular localization and modulation of heat shock proteins in cultured fibroblasts from patients with extrathyroid manifestations of Graves' disease. J. Clin. Endocr. Metab. 73:1991;739-745.
84. Heliovaara M., Aho K., Aromaa A., Knekt P., Reunanen A. Smoking and the risk of rheumatoid arthritis. J. Rheumatol. 20:1993;1830-1835.
85. Winsa B., Mandahl A., Karlsson F. A. Graves' disease, endocrine ophthalmopathy, and smoking. Acta Endocrinol. 128:1993;156-160.
86. Bodenheimer H. C., Schaffner F. Primary biliary cirrhosis and the immune system. Am. J. Gastroenterol. 72:1979;285-296.
87. Alcaron-Segovia D., Diaz-Joanen E., Fishbein E. Features of Sjögren's syndrome in primary biliary cirrhosis. Ann. Int. Med. 79:1973;31-36.
88. Crowe J. P., Christensen E., Butler J., Wheeler P., Doniach D., Keenan J., Williams R. Primary biliary cirrhosis: The prevalence of hyperthyroidism and its relationship to thyroid antibodies and Sicca syndrome. Gastroenterology. 78:1980;1437-1441.
89. Tsianos E. V., Hoofnagle J. H., Fox P. C., Alspaugh M., Jones E. A., Schafer D., Moutsopoulos H. M. Sjögren's syndrome in patients with primary biliary cirrhosis. Hepatology. 11:1990.
90. Heathcote J. The clinical expression of primary biliary cirrhosis. Semin. Liv. Dis. 17:1997;23-33.
91. Elta G. H., Spersky R. A., Goldberg M. J., Connors C. M., Miller K. B. Increased incidence of hypothyroidism in primary biliary cirrhosis. Digest. Dis. Sci. 28:1983;971-975.
92. Reynolds T. B., Denison E. K., Frankl H. D., Lieberman F. L., Peters R. L. Primary biliary cirrhosis with scleroderma, Raynaud's phenomenon and telangiectasia: New syndrome. Am. J. Med. 50:1971;302-312.
93. Hall S., Axelsen P. H., Larson D. E., Bunch T. W. Systemic lupus erythematosus developing in patients with primary biliary cirrhosis. Ann. Int. Med. 100:1984;388-389.
94. Arnason B. G. Multiple sclerosis, allied central nervous system diseases, and immune-mediated neuropathies. Rose N. R., Mackay I. R. Multiple Sclerosis, Allied Central Nervous System Diseases, and Immune-Mediated Neuropathies. 1985;399-427 Harcourt Brace Jovanovich, London.
95. Hogancamp W. E., Rodriguez M., Weinshenker B. G. The epidemiology of multiple sclerosis. Mayo Clin. Proc. 72:1997;871-878.
96. Wynn D. R., Rodriguez M., O'Fallon W. M., Kurland L. T. A reappraisal of the epidemiology of multiple sclerosis in Olmstead County, Minnesota. Neurology. 40:1990;780-786.
97. Svenson L. W., Woodhead S. E., Platt G. H. Regional variations in the prevalence rates of multiple sclerosis in the province of Alberta, Canada. Neuroepidemiology. 13:1994;8-13.
98. Sweeney V. P., Sadovnick A. D., Brandejs V. Prevalence of multiple sclerosis in British Columbia. Canad. J. Neurol. Sci. 13:1986;47-51.
99. Hader W. J., Elliot M., Ebers G. C. Epidemiology of multiple sclerosis in London and Middlesex County, Ontario, Canada. Neurology. 38:1988;617-621.
100. Poser C. M. The epidemiology of multiple sclerosis: a general overview. Ann. Neurol. 36:1994;S180-S193.
101. Kuroiwa Y., Shibasaki H., Ikeda M. Prevalence of multiple sclerosis and its north-to-south gradient in Japan. Neuroepidemiology. 2:1983;62-69.
102. Hou J. B., Zhang Z. Prevalence of multiple sclerosis: a doot to door survey in Lan Cang La Hu Zu Autonomous County, Yunnan Province of China. Neuroepidemiology. 11:1992;52.
103. Sadnovick A. D., Baird P. A., Ward R. H. Multiple sclerosis: updated risks for relatives. Am. J. Med. Genet. 29:1988;533-541.
104. Sadnovick A. D., Armstrong H., Rice G. P. A. A population-based study of multiple sclerosis in twins: Update. Ann. Neurol. 33:1993;281-285.
105. Ann. Neurol. 32:1992;724-727.
106. Birk K., Rudick R. Pregnancy and multiple sclerosis. Arch. Neurol. 43:1986;719-726.
107. Korn-Lubetski I., Kahana E., Cooper G., Abramsky O. Activity of multiple sclerosis during pregnancy and puerperium. Ann. Neurol. 16:1984;229-231.
108. Hunt J. S. Immunobiology of pregnancy. Curr. Opin. Immunol. 4:1992;591-596.
109. Formby B. Immunologic response in pregnancy. Endocrinol. Metab. Clin. North Am. 24:1995;187-205.
110. Wilder R. L. Hormones, pregnancy, and autoimmune diseases. Ann. N. Y. Acad. Sci. 840:1998;45-50.
111. Delassus S., Coutinho G. C., Saucier C., Darche S., Kourilsky P. Differential cytokine expression in maternal blood and placenta during murine gestation. J. Immunol. 152:1994;2411-2420.
112. Cadet P., Rady P. L., Tyring S. K., Yandell R. B., Hughes T. K. Interleukin-10 messenger ribonucleic acid in human placenta: Implications of a role for interleukin-10 in fetal allograft protection. Am. J. Obstet. Gynecol. 173:1995;25-29.
113. Elenkov I. J., Papanicolaou D. A., Wilder R. L., Chrousos G. P. Modulatory effects of glucocorticoids and catecholamines on human interleukin-12 and interleukin-10 production: Clinical implications. Proc. Assoc. Am. Phys. 108:1996;374-381.
114. Piccinni M. P., Giudizi M. G., Biagiotti R., Beloni L., Giannarini L., Sampognaro S., Parronchi P., Manetti R., Annunziato F., Livi C. Progesterone favors the development of human T helper cells producing Th2-type cytokines and promotes both IL-4 production and membrane CD30 expression in established Th1 cell clones. J. Immunol. 155:1995;128-133.
115. Weynard C. M., Schmidt D., Wagner U., Goronzy J. J. The influence of sex on the phenotype of rheumatoid arthritis. Arthritis Rheum. 41:1998;817-822.
116. Del Puente A., Knowler W. C., Pettit D. J. High incidence and prevalence of rheumatoid arthritis in Pima Indians. Am. J. Epidemiol. 129:1989;1170-1178.
117. Harvey J., Arnett F. C., Bias W. B. Heterogeneity of HLA-DR4 in the rheumatoid arthritis of a Chippewa band. J. Rheumatol. 8:1981;797-803.
118. Lau E., Symmons D., Bankhead C. Low prevalence of rheumatoid arthritis in the urbanized Chinese of Hong Kong. J. Rheumatol. 20:1993;1133-1137.
119. Silman A. J., Ollier W., Holligan S. Absence of rheumatoid arthritis in a rural Nigerian population. J. Rheumatol. 20:1993;618-622.
120. Silman A. J., Hochberg M. C. Epidemiology of the Rheumatic Diseases. 1993;Oxford Univ. Press, New York.
121. Alcaron G. S. Epidemiology of rheumatoid arthritis. Rheum. Dis. Clin. North Am. 21:1995;589-604.
122. Kwoh C. K., Venglish C., Lynn A. H., Whitley D. M., Young E., Chakravati A. Age, sex and the familial risk of rheumatoid arthritis. Am. J. Epidemiol. 144:1996;15-24.
123. Hochberg M. C., Spector T. D. Epidemiology of rheumatoid arthritis: Update. Epidemiol. Rev. 12:1990;247-252.
124. Jawasheer D., Thompson W., MacGregor A. J. "Homozygosity:" For the HLA-DR shared epitope contributes the highest risk for rheumatoid arthritis concordance in identical twins. Arthritis Rheum. 37:1994;681-686.
125. Gregersen P. K. T-cell receptor-major histocompatibility complex genetic interactions in rheumatoid arthritis. Rheum. Dis. Clin. North Am. 18:1992;793-807.
126. Wingrave S. J., Kay C. R. Royal College of General Practitioners study: Reduction in incidence of rheumatoid arthritis associated with oral contraceptives. Lancet. 1:1978;569-571.
127. Linos A., Worthington J. W., O'Fallon W. M. The epidemiology of rheumatoid arthritis in Rochester, Minnesota: A study of incidence, prevalence and mortality. Am. J. Epidemiol. 111:1980;87-98.
128. Nelson J. L., Koepsell T. D., Dugowson C. E. Fecundity before disease onset in women with rheumatoid arthritis. Arthritis Rheum. 36:1993;7-14.
129. Klippel J. H. Systemic lupus erythematosus: Demographics, prognosis and outcome. J. Rheumatol. 24:1997;67-71.
130. Hopkinson N. D., Doherty M., Powell R. J. Clinical features and race-specific incidence/prevalence rates of systemic lupus erythematosus in a geographically complete cohort of patients. Ann. Rheum. Dis. 53:1994;675-680.
131. Ferrell P. B., Tan E. M. Systemic lupus erythematosus. Rose N. R., Mackay I. R. Systemic Lupus Erythematosus. 1985.
132. McGrath H., Bell J. M., Haycock J. W. Fluorescent light activates the imunomodulator cis-urocanic acid in vitro: Implications for patients with systemic lupus erythematosus. Ann. Rheum. Dis. 53:1994;396-399.
133. Byrne P. A. C., Williams B. D., Pritchard M. H. Minocycline-related lupus. Br. J. Rheumatol. 33:1994;674-676.
134. Siam A. R. M., Hammoudeh M. Sulfasalazine-induced systemic lupus erythematosus in patients with rheumatoid arthritis. J. Rheumatol. 20:1993;207.
135. Caramaschi P., Biasi D., Carletto A., Manzo T., Bambara L. M. Clobazam-induced lupus erythematosus. Lupus. 3:1994;69.
136. Jacobson D. L., Gange S. J., Rose N. R., Graham N. M. H. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin. Immunol. Immunopathol. 84:1997;223-243.